Alzheimer's Disease, Mild-To-Moderate Alzheimer's Disease
Conditions
Brief summary
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease
Interventions
OTHERPlasma
1 unit of Plasma From Young Donors (Male, aged 30 or younger)
Sponsors
Alkahest, Inc.
Stanford University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of probable Alzheimer's disease (NIA-AA criteria) * Mini-Mental State Examination (MMSE) score 12-24 * Availability of a study partner who knows the patient well and is willing to accompany the subject to all trial visits, to participate in questionnaires and to complete daily journal assessments
Exclusion criteria
* Pregnancy or unwilling to use adequate birth control method for duration of and 6 months beyond study participation * Positive for Hepatitis B, Hepatitis C or HIV at screening * Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study * Related to medical history: * Stroke * Anaphylaxis * Prior adverse reaction to any human blood product * Any history of a blood coagulation disorder or hypercoagulability * Congestive heart failure * Uncontrolled hypertension * Renal failure * Prior intolerance to intravenous fluids * Recent history of uncontrolled atrial fibrillation * IgA deficiency (by history) * Related to medications or other treatments: * Any concurrent use of an anticoagulant therapy. Antiplatelet drugs (e.g., aspirin or clopidogrel) are acceptable * Initiation or change in the dosage of a cholinesterase inhibitor or memantine during the trial. A participant already on a cholinesterase inhibitor or memantine must be on a stable dose for at least one month prior to Screening * Concurrent participation in another treatment trial for Alzheimer's disease. If there was prior participation, the last dose of the investigational agent must have been at least 6 months prior to Screening * Treatment with any human blood product, including intravenous immunoglobulin, during the 6 months prior to Screening or during the trial * Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics, long-acting opioids, or other medications that, in the investigator's opinion, interfere with cognition. Intermittent treatment with short-acting benzodiazepines or atypical antipsychotics may be permitted, provided that no dose is administered within the 72 hours preceding any cognitive assessment * Related to magnetic resonance imaging: * Claustrophobia * Any metallic surgical implant, like a pacemaker or clip that is incompatible with 3T MRI. Certain metallic implants like joint replacements may be permitted, provided that specific manufacturer specifications are available and that the device is known to be safe for 3T MRI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility. | 9 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change on the Clinical Dementia Rating scale Sum of Boxes (CDR-SB) | 9 weeks |
| Change on the Functional Activities Questionnaire (FAQ) | 9 weeks |
| Change on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) | 9 weeks |
| Change on the Geriatric Depression Scale | 9 weeks |
| Change on the Neuropsychiatric Inventory Questionnaire (NPI-Q) | 9 weeks |
| Change on the 13-item ADAS-Cog | 9 weeks |
| Change on the Trail-Making Test | 9 weeks |
Other
| Measure | Time frame |
|---|---|
| In vivo assessment of plasma samples to determine their potential histological effects on the hippocampus and their potential behavioral effects in animal models of cognition | 9 weeks |
| Differential effect of therapy on above outcomes as a function of ApoE genotype | 9 weeks |
| Change in functional connectivity in the default mode network as assessed by resting state functional MRI | 9 weeks |
| Compositional assessment of plasma using in vitro analytical methods. The goal is to assess plasma components that might be associated with aging and/or Alzheimer's disease | 9 weeks |
Countries
United States
Outcome results
None listed